Hydromer Announces Strategic Investment by JMEDTECH and Board Restructuring to Enhance Global Medical Device Coating Platform

Hydromer, Inc. has announced a strategic investment from JMEDTECH alongside the formation of a new Board of Directors, positioning the company for accelerated global growth in medical device coating technologies. The partnership establishes a future-oriented global medical device coating platform that integrates UV-curable and thermal-cure coating systems supported by advanced coating equipment and regionalized services.

The collaboration represents a significant milestone for both companies, amplifying Hydromer's technological and brand influence while marking a critical step in JMEDTECH's global expansion strategy. By uniting capabilities across Asia and the Americas, the partnership establishes a mirror-delivery network covering major medical device markets worldwide. This enhanced infrastructure significantly improves supply chain resilience and responsiveness, creating greater value for customers across the medical device industry.

Michael Torti will continue to serve as CEO and Director, working alongside Chairman Jacqueline Zhang and the newly formed Board to provide strong leadership and industry expertise. The leadership team brings deep experience to guide Hydromer through its next phase of growth and innovation. The company expressed gratitude to departing directors Braeden Lichti and George Kovalyov for their leadership and contributions to the organization.

Hydromer brings over 44 years of expertise in hydrophilic, thromboresistant, and antimicrobial coating technologies to the partnership. The company's extensive experience in surface modification and coating solutions positions it as a valuable partner in developing comprehensive solutions spanning research and development, validation, and mass production. The combined capabilities will offer one of the broadest ranges of coating technologies available in the global medical device marketplace, including automatic large-scale coating systems.

The strategic investment and partnership come at a time when the medical device industry faces increasing demands for advanced coating technologies that improve device performance and patient outcomes. The enhanced global platform addresses growing needs for reliable supply chains and comprehensive coating solutions that meet rigorous regulatory standards. Hydromer's facilities maintain compliance with Good Manufacturing Practice, ISO 13485, and ISO 9001 standards, ensuring consistent quality across all operations.

This development strengthens Hydromer's position as a dominant player in medical device coatings while providing customers with access to expanded technological capabilities and geographic coverage. The partnership demonstrates how strategic investments and global collaborations can drive innovation and improve service delivery in the competitive medical technology sector. The enhanced platform offers medical device manufacturers more options for developing and producing coated devices that meet evolving market requirements and regulatory standards.